International Pharmaceutical Aerosol Consortium on Regulation & Science

The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data, and conducting joint research and development projects. Representing the OINDP industry since 2000, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.

News and Events

May 2021
Read the IPAC-RS 2020 Year in Review to lean more about IPAC-RS's achievements and the benefits of membership.   
The report highlights the impressive work IPAC-RS accomplished in 2020 and showcases the important role our member companies’ played in responding to the global pandemic.  
 
 
IPACRS YIR 2020 Cover.PNG
May 2021
IPAC-RS engages actively in reviewing and commenting on regulatory developments around the world, and works collaboratively with all stakeholders to improve science-based regulations affecting orally inhaled and intranasal pharmaceutical products.  IPAC-RS has prepared a summary of relevant global regulatory developments in 2020.   

 

November 2020
IPAC-RS Regulatory Roundtable Webinar Series
IPAC-RS hosted a Roundtable: A Conversation with the FDA: Perspectives in the Time of COVID-19 on November 2, 2020.

Click here to review the summary of the webinar.

 

Become an IPAC-RS member today!

Inquire below.

Thanks for submitting!